The differential expression analysis across cancers showed that GREB1L mRNA expression was significantly higher in BRCA (p = 1e-05), cholangiocarcinoma (CHOL) (p = 0.02), kidney renal papillary cell carcinoma (KIRP) (p = 7.2e-03), liver hepatocellular carcinoma (LIHC) (p = 2.5e-13), lung adenocarcinoma (LUAD) (p = 1.9e-16), lung squamous cell carcinoma (LUSC) (p = 1.7e-07), pancreatic adenocarcinoma (PAAD) (p = 0.03), and pheochromocytoma and paraganglioma (PCPG) (p = 0.02) tissues than in adjacent normal tissues. This evidence concerns the gene GREB1L and paraganglioma.